Despite Rival's Supply Problems, No Guarantee That Shire Will Re-File Replagal In U.S.
This article was originally published in The Pink Sheet Daily
Human Genetic Therapies division President Gregoire also says self-administration should be a key point of differentiation for Firazyr in the HAE market.
You may also be interested in...
FDA’s Cardiovascular and Renal Drugs Advisory Committee will assess Shire biologics’ BLA for the Fabry disease therapy, which already is available in the U.S. due to shortages of competitor Fabrazyme, during a March 27 meeting.
News about Inhibitex, Gilenya, Genzyme manufacturing, Forest's linaclotide, and Paula Deen
Since 2008, Shire PLC 's market cap has nearly doubled ($8.3 billion to $16 billion) and its employee count has grown from 1,600 to roughly 4,300. Analysts say the U.K. company is on track to deliver its revenue guidance of 15% compound annual growth rate (CAGR) through 2015 – far above the expected anemic performance of most pharmaceutical companies.